[Executive Summary & Recent Highlights](index=1&type=section&id=Executive%20Summary%20%26%20Recent%20Highlights) Adaptive Biotechnologies reported Q1 2024 revenue of $41.9 million, driven by 52% MRD business growth, and strategically reorganized to separate MRD and Immune Medicine operations - Implemented a strategic reorganization to operate MRD and Immune Medicine businesses with dedicated resources, separate segment reporting, and disciplined capital allocation[1](index=1&type=chunk)[2](index=2&type=chunk) - The FDA's Oncologic Drug Advisory Committee (ODAC) unanimously supported using MRD as a primary endpoint for accelerated approval of new multiple myeloma therapies[2](index=2&type=chunk) - Initiated antibody discovery campaigns in Immune Medicine for multiple sclerosis and type 1 diabetes to generate preclinical data in 2024[2](index=2&type=chunk) Q1 2024 Key Performance Indicators | Metric | Value | YoY Growth | | :--- | :--- | :--- | | Total Revenue | $41.9 million | 11% | | MRD Business Revenue | $32.6 million | 52% | | clonoSEQ Test Volume | 17,040 tests | 41% | [Q1 2024 Financial Performance](index=1&type=section&id=Q1%202024%20Financial%20Performance) Q1 2024 total revenue increased 11% to $41.9 million, with operating expenses decreasing 4% to $90.6 million, resulting in a reduced net loss and improved Adjusted EBITDA loss [Consolidated Results](index=1&type=section&id=Consolidated%20Results) Q1 2024 total revenue increased to $41.9 million, while operating expenses decreased to $90.6 million, narrowing the net loss to $47.5 million or ($0.33) per share Q1 2024 Consolidated Statement of Operations Summary (in millions, except per share data) | Metric | Q1 2024 | Q1 2023 | Change | | :--- | :--- | :--- | :--- | | Total Revenue | $41.9 | $37.6 | +11% | | Total Operating Expenses | $90.6 | $94.8 | -4% | | Net Loss | ($47.5) | ($57.7) | Improved | | Net Loss Per Share | ($0.33) | ($0.40) | Improved | [Non-GAAP Measures (Adjusted EBITDA)](index=2&type=section&id=Non-GAAP%20Measures%20(Adjusted%20EBITDA)) The company's non-GAAP Adjusted EBITDA loss for Q1 2024 improved to $28.2 million from $37.1 million in Q1 2023, reflecting better cost management Adjusted EBITDA (Non-GAAP) (in millions) | Period | Adjusted EBITDA Loss | | :--- | :--- | | Q1 2024 | ($28.2) | | Q1 2023 | ($37.1) | [Segment Performance](index=1&type=section&id=Segment%20Performance) In Q1 2024, the MRD business achieved 52% revenue growth and narrowed its operating loss, while the Immune Medicine business saw a 43% revenue decline despite reduced expenses [MRD Business](index=1&type=section&id=MRD%20Business) The MRD business revenue surged 52% to $32.6 million in Q1 2024, driven by a 41% increase in clonoSEQ test volumes, and its Adjusted EBITDA loss improved to $17.3 million MRD Business Performance (in millions) | Metric | Q1 2024 | Q1 2023 | YoY Change | | :--- | :--- | :--- | :--- | | Revenue | $32.6 | $21.4 | +52% | | Operating Expenses | $59.9 | $56.0 | +7% | | Adjusted EBITDA Loss | ($17.3) | ($26.4) | +34% Improvement | [Immune Medicine Business](index=1&type=section&id=Immune%20Medicine%20Business) The Immune Medicine business revenue decreased 43% to $9.2 million in Q1 2024, with operating expenses reduced by 25% to $23.8 million, and its Adjusted EBITDA loss narrowed to $6.9 million Immune Medicine Business Performance (in millions) | Metric | Q1 2024 | Q1 2023 | YoY Change | | :--- | :--- | :--- | :--- | | Revenue | $9.2 | $16.2 | -43% | | Operating Expenses | $23.8 | $31.7 | -25% | | Adjusted EBITDA Loss | ($6.9) | ($7.4) | +7% Improvement | [Financial Position](index=2&type=section&id=Financial%20Position) As of March 31, 2024, Adaptive Biotechnologies maintained a solid liquidity position with $308.9 million in cash, cash equivalents, and marketable securities, with total assets at $620.3 million Key Balance Sheet Items (in millions) | Account | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Cash, cash equivalents & marketable securities | $308.9 | $346.4 | | Total Assets | $620.3 | $661.1 | | Total Liabilities | $345.6 | $352.9 | [2024 Updated Financial Guidance](index=2&type=section&id=2024%20Updated%20Financial%20Guidance) The company updated its full-year 2024 financial guidance, raising the lower end of MRD business revenue forecast and lowering total company operating expense expectations - MRD business full-year revenue guidance was updated to a range of **$135 million to $140 million**, from the previous range of **$130 million to $140 million**[5](index=5&type=chunk) - Full-year total company operating expenses are now expected to be between **$350 million and $360 million**, down from the previous range of **$360 million to $370 million**[5](index=5&type=chunk) - No revenue guidance is provided for the Immune Medicine business[5](index=5&type=chunk) [Appendix: Financial Statements and Reconciliations](index=5&type=section&id=Appendix%3A%20Financial%20Statements%20and%20Reconciliations) This appendix provides detailed unaudited financial statements for Q1 2024, including consolidated statements of operations, balance sheets, and Adjusted EBITDA reconciliations [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Presents the company's unaudited condensed consolidated statements of operations for the period ended March 31, 2024 [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Details the company's unaudited condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023 [Adjusted EBITDA Reconciliation](index=7&type=section&id=Adjusted%20EBITDA%20Reconciliation) Provides a reconciliation of GAAP net loss to non-GAAP Adjusted EBITDA for the reported periods [Segment Information](index=8&type=section&id=Segment%20Information) Presents detailed financial information for the company's MRD and Immune Medicine business segments

Core Insights - Adaptive Biotechnologies Corporation has concluded its strategic review, deciding to operate its Minimal Residual Disease (MRD) and Immune Medicine businesses independently while maintaining a strong capital position to support both segments [2][4] Business Update - The company reported preliminary revenue for Q1 2024, estimating total revenue between $41 million and $43 million, reflecting a 12% increase compared to Q1 2023 [3] - MRD revenue is projected to be between $31 million and $32 million for Q1 2024, marking a significant 47% increase from the same period last year [3] CFO Transition - Tycho Peterson, the current CFO, will be leaving the company, and Kyle Piskel, who has been with Adaptive for 8 years, will take over as the new CFO [4][5] - Kyle Piskel has previously served as the Interim CFO and brings over 15 years of financial expertise to the role [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (St ...

Financial Data and Key Metrics Changes - Total revenue for 2023 was $170.3 million, an 8% decrease year-over-year [16] - Q4 revenue was $45.8 million, with 67% from MRD and 33% from Immune Medicine [15] - MRD revenue for the full year was $102.7 million, up 18% from the previous year, while Immune Medicine revenue was $67.5 million, down 31% [16] - Gross margin for Q4 was 57%, an 8-point increase from Q3 but a 13-point decline year-over-year [17] - Net loss for the full year was $225.3 million, compared to $200.4 million in 2022 [18] Business Line Data and Key Metrics Changes - MRD business grew 27% year-over-year excluding milestones, driven by clonoSEQ volume growth [5][6] - clonoSEQ clinical revenue in Q4 grew 56% year-over-year, with test volumes increasing by 49% [7][8] - Immune Medicine revenue decreased by 45% year-over-year, primarily due to lower Genentech amortization [16] Market Data and Key Metrics Changes - The MRD business is expected to contribute between $130 million and $140 million in revenue for 2024, with a conservative growth outlook for Pharma services [19] - The company anticipates a 45% to 55% revenue split between the first and second halves of 2024 [20] Company Strategy and Development Direction - The company is focusing on a strategic review to maximize shareholder value, with plans to communicate outcomes by the end of the current quarter [7] - The MRD business aims to reach profitability by the end of 2025, while the Immune Medicine segment will focus on targeted drug discovery [6][12] - The company is enhancing its customer experience through EMR integrations and partnerships, including a new agreement with Flatiron Health [10][13] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of the clonoSEQ MRD business and the potential of the Immune Medicine pipeline [22] - The company is optimistic about the impact of state biomarker laws on business, although these benefits are not included in the 2024 guidance [80] Other Important Information - The company ended 2023 with approximately $346 million in cash equivalents, allowing for strategic investments [18] - The company is implementing operational efficiencies to reduce burn rate to an average of $35 million per quarter in 2024 [20] Q&A Session Summary Question: Can you walk through the OpEx outlook for '24 and the revenue considerations for burn? - Management indicated a burn rate of $35 million per quarter, emphasizing ongoing efficiency drives across the organization [24] Question: What are the expectations for MRD revenue cadence in the year? - Management noted that Q4 typically has fewer business days, impacting growth rates, but leading indicators remain positive [32] Question: Can you elaborate on the strategic review outcome expected at the end of the quarter? - Management refrained from commenting on specific structures but emphasized a strong cash position and commitment to maximizing stakeholder value [29] Question: What are the trends in the MRD Pharma side, specifically regarding cancellations or delays? - Management noted a decline in the number of trials in multiple myeloma, impacting growth opportunities, while non-Hodgkins lymphoma remains stable [66] Question: Can you provide details on the partnership with Flatiron Health? - The partnership involves a setup fee and an annual fee, with no milestone payments specified [74] Question: How is the Epic integration performing? - Feedback has been positive, with increased volumes and reduced manpower for order entry noted [75]

Fourth Quarter and FY 2023 Earnings Conference Call Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation ...

SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Adaptive Biotechnologies’ management is scheduled to present on Tuesday, January 9th at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Tycho Peterson - CFO Nitin Sood - Chief Commercial Officer, MRD Susan Bobulsky - Senior Vice President, Diagnostics, clonoSEQ Sharon Benzeno - Chief Commercial Officer, Immune Medicine Conference Call Participants Mark Massaro - BTIG Dan Brennan - TD Cowen David Westenberg - Piper Sandler Operator Thank you for stan ...

Third Quarter 2023 Earnings Conference Call Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation of an o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-09 ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q2 2023 Results Conference Call August 2, 2023 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Tycho Peterson - CFO Nitin Sood - Chief Commercial Officer, MRD Harlan Robins - Chief Scientific Officer and Co-founder Sharon Benzeno - Chief Commercial Officer, Immune Medicine Conference Call Participants Rachel Vatnsdal - JPMorgan Chase Dan Brennan - TD Cowen David Westenberg - Piper Sandler Mark Massaro - BTIG Eli ...